$870,000 of BRISTOL-MYERS SQUIBB COMPANY lobbying was just disclosed, from Q1 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Discussions regarding promoting health equity International Reference Pricing/Most Favored Nation, regarding all bio-pharmaceutical issues Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 MINI Act ORPHAN Act Mental Health Appropriations Language FY26 Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation Intellectual Property Reform concerning bio-pharmaceutical industry H.R.830, HELP Copays Act of 2023 S.127, Pharmacy Benefit Manager Transparency Act of 2023 H.R.3283, Fairness for Patient Medications Act S.1339, Pharmacy Benefit Manager Reform Act H.R.5378, Lower Costs, More Transparency Act S.2973, Modernizing and Ensuring Equity Act H.R.8412, Clinical Trials Modernization Act"
You can find more data on corporate lobbying on Quiver Quantitative.
BMY Congressional Stock Trading
Members of Congress have traded $BMY stock 3 times in the past 6 months. Of those trades, 2 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BMY stock by members of Congress over the last 6 months:
- REPRESENTATIVE GREG LANDSMAN sold up to $15,000 on 03/27.
- REPRESENTATIVE JULIE JOHNSON purchased up to $15,000 on 01/15.
- REPRESENTATIVE VIRGINIA FOXX purchased up to $15,000 on 12/06.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
BMY Insider Trading Activity
BMY insiders have traded $BMY stock on the open market 4 times in the past 6 months. Of those trades, 3 have been purchases and 1 have been sales.
Here’s a breakdown of recent trading of $BMY stock by insiders over the last 6 months:
- SAMIT HIRAWAT (EVP,Chief Med.Offr.,Drug Dev.) has made 2 purchases buying 3,653 shares for an estimated $200,055 and 0 sales.
- CHRISTOPHER S. BOERNER (Chief Executive Officer) purchased 2,000 shares for an estimated $110,096
- PHIL M HOLZER (SVP and Controller) sold 700 shares for an estimated $38,930
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BMY Hedge Fund Activity
We have seen 1,091 institutional investors add shares of BMY stock to their portfolio, and 1,027 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 18,093,184 shares (+23.2%) to their portfolio in Q4 2024, for an estimated $1,023,350,487
- FMR LLC removed 13,829,790 shares (-30.8%) from their portfolio in Q4 2024, for an estimated $782,212,922
- PRICE T ROWE ASSOCIATES INC /MD/ removed 12,711,872 shares (-62.8%) from their portfolio in Q4 2024, for an estimated $718,983,480
- AMERIPRISE FINANCIAL INC added 12,011,983 shares (+59.9%) to their portfolio in Q4 2024, for an estimated $679,397,758
- DZ BANK AG DEUTSCHE ZENTRAL GENOSSENSCHAFTS BANK, FRANKFURT AM MAIN added 10,913,708 shares (+701.2%) to their portfolio in Q4 2024, for an estimated $617,279,324
- TWO SIGMA ADVISERS, LP removed 7,692,600 shares (-80.5%) from their portfolio in Q4 2024, for an estimated $435,093,456
- WELLINGTON MANAGEMENT GROUP LLP added 5,827,317 shares (+3880.0%) to their portfolio in Q4 2024, for an estimated $329,593,049
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BMY Analyst Ratings
Wall Street analysts have issued reports on $BMY in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Daiwa issued a "Outperform" rating on 11/13/2024
To track analyst ratings and price targets for BMY, check out Quiver Quantitative's $BMY forecast page.
BMY Price Targets
Multiple analysts have issued price targets for $BMY recently. We have seen 2 analysts offer price targets for $BMY in the last 6 months, with a median target of $59.0.
Here are some recent targets:
- Evan Seigerman from BMO Capital set a target price of $61.0 on 11/12/2024
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
